{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:08:21Z","timestamp":1788433701091,"version":"build-2803163510"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Imaging studies suggest potential changes to the classification and assessment of inflammatory musculoskeletal lupus. This is important because of the burden of disease but the potential for new targeted therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Using our current classification and treatment, musculoskeletal symptoms continue to impact significantly on quality of life and work disability. Ultrasound and MRI studies suggested that new approaches to the diagnosis, classification, and evaluation of these symptoms are needed. Many patients with pain but no synovitis have ultrasound-proven joint and tendon inflammation but would not qualify for clinical trials or score highly on disease activity instruments. MRI studies show that erosions are more common than previously thought and may have a different pathogenesis than RA. Immunology studies suggest differences from other autoimmune synovitis, with a complex role for type I interferons. A wide range of biologic therapies appear more consistently effective for arthritis than some other manifestations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Changes to the selection of patients for therapy and stratification using musculoskeletal imaging may offer new approaches to clinical trials and the routine care of systemic lupus erythematosus patients with inflammatory musculoskeletal symptoms. Outcomes may thereby be improved using existing therapies. There are significant knowledge gaps that must be addressed to achieve these potential improved outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000000421","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T11:20:37Z","timestamp":1498648837000},"page":"486-492","source":"Crossref","is-referenced-by-count":40,"title":["Musculoskeletal manifestations of systemic lupus erythmatosus"],"prefix":"10.1097","volume":"29","author":[{"given":"Khaled","family":"Mahmoud","sequence":"first","affiliation":[{"name":"NIHR Leeds Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust"},{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Zayat","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust"},{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Vital","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust"},{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1191\/0961203303lu2021oa","article-title":"Musculoskeletal involvement in systemic lupus erythematosus","volume":"13","author":"Zoma","year":"2004","journal-title":"Lupus"},{"key":"R3-20230829","first-page":"527","article-title":"Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. I. A descriptive analysis of 704 European lupus patients. European Consensus Study Group for disease activity in SLE","volume":"10","author":"Vitali","year":"1992","journal-title":"Clin Exp Rheumatol"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3109\/03009742.2012.677857","article-title":"An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life","volume":"41","author":"Pettersson","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/rheumatology\/ken477","article-title":"Employment and work disability in systemic lupus erythematosus: a systematic review","volume":"48","author":"Baker","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1177\/0961203309345784","article-title":"Work disability in systemic lupus erythematosus is prevalent and associated with socio-demographic and disease related factors","volume":"18","author":"Baker","year":"2009","journal-title":"Lupus"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/acr.20669","article-title":"Longitudinal study of the impact of incident organ manifestations and increased disease activity on work loss among persons with systemic lupus erythematosus","volume":"64","author":"Yelin","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1002\/art.38731","article-title":"Mortality associated with systemic lupus erythematosus in France assessed by multiple-cause-of-death analysis","volume":"66","author":"Thomas","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/0961203315627202","article-title":"Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis","volume":"25","author":"Lee","year":"2016","journal-title":"Lupus"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/rheumatology\/kew049","article-title":"Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry","volume":"55","author":"Pego-Reigosa","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/annrheumdis-2015-207653","article-title":"Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study","volume":"75","author":"Isenberg","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R12-20230829","first-page":"30","article-title":"Response to rituximab in patients with refractory systemic lupus erythematosus (SLE): results from a national multi-centre register","volume":"54","author":"Sutton","year":"2015","journal-title":"Rheumatology"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0307-742X(21)00010-2","article-title":"Jaccoud's syndrome: a sequel to the joint involvement of systemic lupus erythematosus","volume":"1","author":"Bywaters","year":"1975","journal-title":"Clin Rheum Dis"},{"key":"R14-20230829","first-page":"261","article-title":"Pattern of joint involvement in patients with systemic lupus erythematosus and its association with rheumatoid factor and hypermobility","volume":"46","author":"Caznoch","year":"2006","journal-title":"Rev Bras Reumatol"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/MD.0b013e3181632d18","article-title":"Jaccoud arthropathy in systemic lupus erythematosus: analysis of clinical characteristics and review of the literature","volume":"87","author":"Santiago","year":"2008","journal-title":"Medicine (Baltimore)"},{"key":"R16-20230829","first-page":"65","article-title":"Deforming arthropathy of the hands in systemic lupus erythematosus","volume":"15","author":"Alarcon-Segovia","year":"1988","journal-title":"J Rheumatol"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/rheumatology\/37.4.421","article-title":"Erosive arthritis in systemic lupus erythematosus: analysis of a distinct clinical and serological subset","volume":"37","author":"Richter Cohen","year":"1998","journal-title":"Br J Rheumatol"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10067-015-3127-3","article-title":"Chronic arthritis in systemic lupus erythematosus: distinct features in 336 paediatric and 1830 adult patients","volume":"35","author":"Gormezano","year":"2016","journal-title":"Clin Rheumatol"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/rheumatology\/ker381","article-title":"Lupus arthritis: do we have a clinically useful classification?","volume":"51","author":"Ball","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/nrrheum.2012.200","article-title":"Connective tissue diseases: SLE-associated arthropathy: truly a benign entity?","volume":"8","author":"Murphy","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"R21-20230829","first-page":"485","article-title":"The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review","volume":"55","author":"Zayat","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"633.3","DOI":"10.1136\/annrheumdis-2015-eular.1827","article-title":"The role of musculoskeletal ultrasound in the stratification of SLE; a multicenter cross-sectional study","volume":"74","author":"Zayat","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/annrheumdis-2016-eular.4534","article-title":"An evaluation of clinical outcome measures for musculoskeletal lupus using ultrasound as a gold standard","volume":"75","author":"Mahmoud","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/rheumatology\/kes226","article-title":"Joint and tendon involvement in systemic lupus erythematosus: an ultrasound study of hands and wrists in 108 patients","volume":"51","author":"Gabba","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/annrheumdis-2016-eular.4555","article-title":"A prospective study to assess responsiveness of clinical and ultrasound outcome measures for musculoskeletal SLE","volume":"75","author":"Zayat","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1093\/rheumatology\/keu215","article-title":"A study of erosive phenotypes in lupus arthritis using magnetic resonance imaging and anti-citrullinated protein antibody, anti-RA33 and RF autoantibody status","volume":"53","author":"Ball","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.3899\/jrheum.090338","article-title":"Citrulline dependence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus as a marker of deforming\/erosive arthritis","volume":"36","author":"Kakumanu","year":"2009","journal-title":"J Rheumatol"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/art.27312","article-title":"Mediation of nonerosive arthritis in a mouse model of lupus by interferon-alpha-stimulated monocyte differentiation that is nonpermissive of osteoclastogenesis","volume":"62","author":"Mensah","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jbspin.2015.07.010","article-title":"The roles of interferons in osteoclasts and osteoclastogenesis","volume":"83","author":"Xiong","year":"2016","journal-title":"Joint Bone Spine"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/art.22578","article-title":"Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus","volume":"56","author":"Nzeusseu Toukap","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R31-20230829","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kew431","article-title":"Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis, and targeted therapy","author":"Psarras","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.38628","article-title":"Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures","volume":"66","author":"Chiche","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R33-20230829","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1136\/ard.2005.040477","article-title":"Expression of interferon beta in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis","volume":"64","author":"van Holten","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"R239","DOI":"10.1186\/ar1165","article-title":"Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis","volume":"6","author":"van Holten","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"R35-20230829","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1089\/hum.2006.17.985","article-title":"Intraarticular interferon-beta gene therapy ameliorates adjuvant arthritis in rats","volume":"17","author":"Adriaansen","year":"2006","journal-title":"Hum Gene Ther"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1002\/art.21496","article-title":"Stromal cells and osteoclasts are responsible for exacerbated collagen-induced arthritis in interferon-beta-deficient mice","volume":"52","author":"Treschow","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/ard.2010.129171","article-title":"The interferon regulatory factor 5 gene confers susceptibility to rheumatoid arthritis and influences its erosive phenotype","volume":"70","author":"Dawidowicz","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R38-20230829","first-page":"3530","article-title":"Safety and efficacy of sifalimumab, an anti IFN-alpha monoclonal antibody, in a phase 2b study of moderate to severe systemic lupus erythematosus (SLE)","volume":"66","author":"Khamashta","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R39-20230829","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R40-20230829","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.berh.2009.04.003","article-title":"Lupus arthritis","volume":"23","author":"Grossman","year":"2009","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R41-20230829","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.autrev.2011.06.011","article-title":"The systemic lupus erythematosus responder index (SRI); a new SLE disease activity assessment","volume":"11","author":"Luijten","year":"2012","journal-title":"Autoimmun Rev"},{"key":"R42-20230829","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/art.24068","article-title":"Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial","volume":"59","author":"Fortin","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R43-20230829","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1756-185X.2011.01665.x","article-title":"Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus","volume":"15","author":"Islam","year":"2012","journal-title":"Int J Rheum Dis"},{"key":"R44-20230829","first-page":"1275","article-title":"Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus","volume":"26","author":"Carneiro","year":"1999","journal-title":"J Rheumatol"},{"key":"R45-20230829","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R46-20230829","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"R47-20230829","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","article-title":"Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials","volume":"71","author":"Manzi","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R48-20230829","doi-asserted-by":"crossref","first-page":"e000031","DOI":"10.1136\/lupus-2014-000031","article-title":"Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials","volume":"1","author":"Furie","year":"2014","journal-title":"Lupus Sci Med"},{"key":"R49-20230829","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1002\/art.27601","article-title":"The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis and Rheumatism"},{"key":"R50-20230829","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/art.39085","article-title":"Brief report: responses to rituximab suggest b cell-independent inflammation in cutaneous systemic lupus erythematosus","volume":"67","author":"Vital","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R51-20230829","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1002\/art.30466","article-title":"B cell biomarkers of rituximab responses in systemic lupus erythematosus","volume":"63","author":"Vital","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R52-20230829","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study","volume":"73","author":"Wallace","year":"2014","journal-title":"Ann Rheum Dis"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201709000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T02:45:56Z","timestamp":1693277156000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201709000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000421","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}